Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease.

Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease.

Alzheimer's Disease (AD) is the most prevalent form of dementia worldwide, yet the development of therapeutics has been hampered by the absence of suitable biomarkers to diagnose the disease in its early stages prior to the formation of amyloid plaques and the occurrence of irreversible neurona...

Full description

Bibliographic Details
Main Authors:	Carol Man Gao, Alice Y Yam, Xuemei Wang, Erika Magdangal, Cleo Salisbury, David Peretz, Ronald N Zuckermann, Michael D Connolly, Oskar Hansson, Lennart Minthon, Henrik Zetterberg, Kaj Blennow, Joseph P Fedynyshyn, Sophie Allauzen
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2010-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3012719?pdf=render

Similar Items

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.
by: Mikko Hölttä, et al.
Published: (2013-01-01)

<it>BACE1 </it>gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
by: Minthon Lennart, et al.
Published: (2010-09-01)

Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.
by: Sebastian Palmqvist, et al.
Published: (2012-01-01)

Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.
by: Peder Buchhave, et al.
Published: (2009-01-01)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
by: Ezra Mulugeta, et al.
Published: (2011-01-01)

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
by: Niklas Mattsson, et al.
Published: (2016-03-01)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
by: Henrik Zetterberg, et al.
Published: (2021-02-01)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
by: Ulf Andreasson, et al.
Published: (2016-01-01)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
by: Niels Andreasen, et al.
Published: (2010-01-01)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
by: Niklas Mattsson, et al.
Published: (2010-01-01)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
by: Henrik Zetterberg, et al.
Published: (2010-01-01)

Ubiquitin carboxy-terminal hydrolase L1 <it>(UCHL1) </it>S18Y polymorphism in Alzheimer's disease
by: Andreasen Niels, et al.
Published: (2010-03-01)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
by: Maria Bjerke, et al.
Published: (2010-01-01)

Commentary: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
by: Thomas K. Karikari, et al.
Published: (2018-03-01)

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
by: Carina Wattmo, et al.
Published: (2020-01-01)

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
by: Malin Wennström, et al.
Published: (2015-01-01)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
by: Nicholas J. Ashton, et al.
Published: (2021-06-01)

Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease
by: Joakim Hertze, et al.
Published: (2013-04-01)

No diagnostic value of plasma clusterin in Alzheimer's disease.
by: Edina Silajdžić, et al.
Published: (2012-01-01)

Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease.
by: Maria Björkqvist, et al.
Published: (2012-01-01)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
by: Oskar Hansson, et al.
Published: (2019-04-01)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
by: Claudia Cicognola, et al.
Published: (2021-02-01)

Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer’s disease and other neurodegenerative diseases
by: Melinda Rezeli, et al.
Published: (2015-09-01)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
by: Claudia Cicognola, et al.
Published: (2021-03-01)

Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease
by: Christoffer Rosén, et al.
Published: (2014-07-01)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
by: Lovisa Tobieson, et al.
Published: (2021-08-01)

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
by: Ronald Lautner, et al.
Published: (2017-10-01)

Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment.
by: Per Johansson, et al.
Published: (2017-01-01)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
by: Linn Hermansson, et al.
Published: (2019-01-01)

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
by: Elena Camporesi, et al.
Published: (2021-02-01)

Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity
by: Utku Konca Y, et al.
Published: (2014-05-01)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
by: Nicholas J. Ashton, et al.
Published: (2019-12-01)

No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion.
by: Colin Wallace, et al.
Published: (2018-01-01)

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
by: Niklas Mattsson-Carlgren, et al.
Published: (2020-12-01)

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
by: Niklas Mattsson-Carlgren, et al.
Published: (2021-01-01)

Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study
by: Marie Eckerström, et al.
Published: (2020-12-01)

Repeated lumbar punctures within 3 days may affect CSF biomarker levels
by: Martin Olsson, et al.
Published: (2019-12-01)

Increased CSF levels of phosphorylated neurofilament heavy protein following bout in amateur boxers.
by: Sanna Neselius, et al.
Published: (2013-01-01)

Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study.
by: Lina Bergman, et al.
Published: (2018-01-01)

The octarepeat region of the prion protein is conformationally altered in PrP(Sc).
by: Alice Y Yam, et al.
Published: (2010-01-01)